发布求助
文献互助 智能选刊 最新文献

Nature Reviews Endocrinology最新文献

筛选
英文 中文
Liothyronine treatment for hypothyroidism — a patient’s view 碘甲状腺原氨酸治疗甲状腺功能减退症-一个病人的观点
IF 31 1区 医学
Nature Reviews Endocrinology Pub Date : 2025-05-15 DOI: 10.1038/s41574-025-01124-w
Mary Saunders
{"title":"Liothyronine treatment for hypothyroidism — a patient’s view","authors":"Mary Saunders","doi":"10.1038/s41574-025-01124-w","DOIUrl":"10.1038/s41574-025-01124-w","url":null,"abstract":"Despite its prevalence, treatment of hypothyroidism has long divided opinion in the research and clinical fields. Here, I share my experience as a patient living with hypothyroidism for 16 years, as well as the difficulties I have faced in achieving consistent and effective treatment tailored to my individual needs.","PeriodicalId":18916,"journal":{"name":"Nature Reviews Endocrinology","volume":"21 8","pages":"453-454"},"PeriodicalIF":31.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus 胰淀素：超重、肥胖和糖尿病的新兴治疗机会。
IF 31 1区 医学
Nature Reviews Endocrinology Pub Date : 2025-05-13 DOI: 10.1038/s41574-025-01125-9
Christopher S. Walker, Jacqueline F. Aitken, Greeshma Vazhoor Amarsingh, Shaoping Zhang, Garth J. S. Cooper
{"title":"Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus","authors":"Christopher S. Walker, Jacqueline F. Aitken, Greeshma Vazhoor Amarsingh, Shaoping Zhang, Garth J. S. Cooper","doi":"10.1038/s41574-025-01125-9","DOIUrl":"10.1038/s41574-025-01125-9","url":null,"abstract":"The identification of amylin as a glucoregulatory peptide hormone with roles in meal-ending satiation sparked a surge of experimental development, which culminated in the amylin mimetic drug pramlintide. Pramlintide was approved by the FDA in 2005 for the treatment of type 1 diabetes mellitus and insulin-requiring type 2 diabetes, and was also explored as a novel anti-obesity treatment. Despite this exciting potential, efforts to develop an amylin-based anti-obesity therapeutic stalled owing to challenges around dosage frequency, safety and formulation. Generally, anti-obesity therapies have displayed modest efficacy and mixed safety profiles, leaving a clear unmet clinical need that requires addressing. Advances in peptide chemistry have reinvigorated the amylin field by enabling the manufacture of effective new amylin-based molecules, resulting in therapeutics that are now on the cusp of approval. At present, there are growing concerns around GLP1 receptor agonist-based therapeutics, in particular their association with loss of lean body mass. Additionally, treatment of patients with overweight or obesity without associated comorbidities is increasingly common. The widespread pharmacotherapy of otherwise healthy populations with overweight or obesity with the goal of improving future health requires further regulatory and ethical consideration. This Review describes how amylin controls energy homeostasis and provides a current overview of amylin-based therapeutic development. Amylin is a peptide hormone involved in satiation. Amylin mimetics have potential as therapies for obesity and diabetes mellitus, but clinical development has proven challenging. This Review discusses the physiological roles of amylin and the current progress of amylin mimetic therapeutics.","PeriodicalId":18916,"journal":{"name":"Nature Reviews Endocrinology","volume":"21 8","pages":"482-494"},"PeriodicalIF":31.0,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143945407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prolactin regulates body temperature in pregnancy 催乳素调节怀孕期间的体温
IF 31 1区 医学
Nature Reviews Endocrinology Pub Date : 2025-05-07 DOI: 10.1038/s41574-025-01130-y
Claire Greenhill
{"title":"Prolactin regulates body temperature in pregnancy","authors":"Claire Greenhill","doi":"10.1038/s41574-025-01130-y","DOIUrl":"10.1038/s41574-025-01130-y","url":null,"abstract":"","PeriodicalId":18916,"journal":{"name":"Nature Reviews Endocrinology","volume":"21 7","pages":"396-396"},"PeriodicalIF":31.0,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143915649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The incretin effect — almost magical 肠促胰岛素的效果——几乎是神奇的
IF 31 1区 医学
Nature Reviews Endocrinology Pub Date : 2025-05-07 DOI: 10.1038/s41574-025-01127-7
Rasmus Syberg Rasmussen, Lærke Smidt Gasbjerg
{"title":"The incretin effect — almost magical","authors":"Rasmus Syberg Rasmussen, Lærke Smidt Gasbjerg","doi":"10.1038/s41574-025-01127-7","DOIUrl":"10.1038/s41574-025-01127-7","url":null,"abstract":"","PeriodicalId":18916,"journal":{"name":"Nature Reviews Endocrinology","volume":"21 8","pages":"460-460"},"PeriodicalIF":31.0,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143920026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Individualized and innovative gender healthcare for transgender and nonbinary youth 为跨性别和非二元青年提供个性化和创新的性别保健
IF 31 1区 医学
Nature Reviews Endocrinology Pub Date : 2025-05-07 DOI: 10.1038/s41574-025-01113-z
Drew B. A. Clark, Daniel L. Metzger, Ken C. Pang, Colton St. Amand, Karine Khatchadourian
{"title":"Individualized and innovative gender healthcare for transgender and nonbinary youth","authors":"Drew B. A. Clark, Daniel L. Metzger, Ken C. Pang, Colton St. Amand, Karine Khatchadourian","doi":"10.1038/s41574-025-01113-z","DOIUrl":"10.1038/s41574-025-01113-z","url":null,"abstract":"Increasing numbers of transgender and nonbinary youth are now accessing gender-affirming medical interventions, which have been demonstrated to improve health and well-being. This Perspective addresses how the needs of transgender and nonbinary youth, up to age 18, can be addressed through individualized gender-embodiment care. We first review standard medical therapies, including gonadotropin-releasing hormone analogues, 17β-oestradiol, testosterone, steroidal antiandrogens and progestins, followed by presenting novel approaches to individualizing gender healthcare for transgender and nonbinary youth, consisting of selective oestrogen receptor modulators, 5α-reductase inhibitors, aromatase inhibitors and non-steroidal antiandrogens. Ethical guidance for off-label prescribing is provided, grounded in the principles of evidence, benefit, safety, respect, care, communication, transparency, equity and innovation. These ethical principles are applied in three clinical scenarios in which off-label therapies are considered. We conclude that standard medical therapies are ethically justified and that novel therapies can be ethically acceptable when carefully considered in the context of an individual youth’s care plan and taking into account the available theoretical, clinical and research evidence as well as the potential benefits and potential risks. In keeping with the principle of innovation, we encourage clinicians and researchers to share evidence of medical innovations that support the gender health of transgender and nonbinary youth. Transgender and nonbinary youth are increasingly seeking out gender-affirming medical treatment. This Perspective discusses standard and novel therapies for individualized care of transgender and nonbinary youth as well as the ethical principles guiding the provision of innovative therapies in gender-affirming medical interventions.","PeriodicalId":18916,"journal":{"name":"Nature Reviews Endocrinology","volume":"21 7","pages":"441-452"},"PeriodicalIF":31.0,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143920027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Promising drugs for PCOS: targeting metabolic and endocrine dysfunctions 有前景的多囊卵巢综合征药物：针对代谢和内分泌功能障碍
IF 31 1区 医学
Nature Reviews Endocrinology Pub Date : 2025-05-06 DOI: 10.1038/s41574-025-01121-z
Kaipeng Zhou, Chen Lou, Po-Han Chang, Jingjing Jiang, Yue Zhao, Hsun-Ming Chang, Liangshan Mu
{"title":"Promising drugs for PCOS: targeting metabolic and endocrine dysfunctions","authors":"Kaipeng Zhou, Chen Lou, Po-Han Chang, Jingjing Jiang, Yue Zhao, Hsun-Ming Chang, Liangshan Mu","doi":"10.1038/s41574-025-01121-z","DOIUrl":"10.1038/s41574-025-01121-z","url":null,"abstract":"Emerging pharmaceuticals that target metabolic and endocrine dysfunctions in polycystic ovary syndrome are transforming treatment paradigms. This article covers innovative drugs, including glucagon-like peptide 1 receptor agonists, sodium–glucose cotransporter 2 inhibitors, kisspeptin, neurokinin 3 receptor antagonists and artemisinins, exploring their mechanisms and potential to advance care for this disorder.","PeriodicalId":18916,"journal":{"name":"Nature Reviews Endocrinology","volume":"21 8","pages":"455-456"},"PeriodicalIF":31.0,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143909976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Publisher Correction: Neuro–immuno–endocrinology of the skin: how environment regulates body homeostasis 出版更正：皮肤的神经免疫内分泌学：环境如何调节身体稳态
IF 31 1区 医学
Nature Reviews Endocrinology Pub Date : 2025-05-02 DOI: 10.1038/s41574-025-01126-8
Radomir M. Slominski, Chander Raman, Anton M. Jetten, Andrzej T. Slominski
{"title":"Publisher Correction: Neuro–immuno–endocrinology of the skin: how environment regulates body homeostasis","authors":"Radomir M. Slominski, Chander Raman, Anton M. Jetten, Andrzej T. Slominski","doi":"10.1038/s41574-025-01126-8","DOIUrl":"10.1038/s41574-025-01126-8","url":null,"abstract":"","PeriodicalId":18916,"journal":{"name":"Nature Reviews Endocrinology","volume":"21 8","pages":"513-513"},"PeriodicalIF":31.0,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41574-025-01126-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143901786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to ‘Ensuring diverse representation and minimizing conflicts of interest in clinical practice guidelines’ 回复“确保临床实践指南中的多样化代表和最大限度地减少利益冲突”
IF 31 1区 医学
Nature Reviews Endocrinology Pub Date : 2025-05-01 DOI: 10.1038/s41574-025-01123-x
Ravi Savarirayan, Svein Otto Fredwall
{"title":"Reply to ‘Ensuring diverse representation and minimizing conflicts of interest in clinical practice guidelines’","authors":"Ravi Savarirayan, Svein Otto Fredwall","doi":"10.1038/s41574-025-01123-x","DOIUrl":"10.1038/s41574-025-01123-x","url":null,"abstract":"","PeriodicalId":18916,"journal":{"name":"Nature Reviews Endocrinology","volume":"21 8","pages":"512-512"},"PeriodicalIF":31.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ensuring diverse representation and minimizing conflicts of interest in clinical practice guidelines 在临床实践指南中确保多样化的代表和最大限度地减少利益冲突
IF 31 1区 医学
Nature Reviews Endocrinology Pub Date : 2025-05-01 DOI: 10.1038/s41574-025-01122-y
Andrea Schelhaas, Kara Ayers, Stephanie Meredith, Leah Smith, Katie Stoll
{"title":"Ensuring diverse representation and minimizing conflicts of interest in clinical practice guidelines","authors":"Andrea Schelhaas, Kara Ayers, Stephanie Meredith, Leah Smith, Katie Stoll","doi":"10.1038/s41574-025-01122-y","DOIUrl":"10.1038/s41574-025-01122-y","url":null,"abstract":"","PeriodicalId":18916,"journal":{"name":"Nature Reviews Endocrinology","volume":"21 8","pages":"510-511"},"PeriodicalIF":31.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Replacing body mass index with relative fat mass to accurately estimate adiposity 用相对脂肪量代替身体质量指数来准确估计肥胖
IF 31 1区 医学
Nature Reviews Endocrinology Pub Date : 2025-05-01 DOI: 10.1038/s41574-025-01120-0
Navin Suthahar  , Richard N. Bergman, Rudolf A. de Boer
{"title":"Replacing body mass index with relative fat mass to accurately estimate adiposity","authors":"Navin Suthahar \u0000 , Richard N. Bergman, Rudolf A. de Boer","doi":"10.1038/s41574-025-01120-0","DOIUrl":"10.1038/s41574-025-01120-0","url":null,"abstract":"Body mass index (BMI), as its name indicates, is a marker of total body mass and not a specific marker of adipose tissue mass. Here, we position relative fat mass (RFM) as an ideal alternative to BMI by highlighting the superior performance of RFM in assessing cardiometabolic risk.","PeriodicalId":18916,"journal":{"name":"Nature Reviews Endocrinology","volume":"21 7","pages":"393-394"},"PeriodicalIF":31.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143893195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信